NasdaqGS:ARWRBiotechs
Arrowhead Pharmaceuticals (ARWR) Is Up 5.9% After Durable Two-Year Plozasiran Data in Severe Hypertriglyceridemia
In March 2026, Arrowhead Pharmaceuticals reported two-year open-label extension data showing durable triglyceride reductions and consistent safety for investigational plozasiran in patients with severe and mixed hypertriglyceridemia, building on earlier Phase 2b results and supporting ongoing global Phase 3 programs and regulatory plans.
The data underscored plozasiran’s potential to address a lack of long-term treatment options in severe lipid disorders, including rare Familial...